On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Lexicon Pharmaceuticals, (NASDAQ:LXRX), Wayfair (NYSE:W), Cyberark Software (NASDAQ:CYBR), Ebix (NASDAQ:EBIX)
On March 18, 2015 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Ipsen S.A. (Euronext: IPN; ADR: IPSEY) disclosed that they have entered into an agreement for Ipsen, upon regulatory approval, to commercialize telotristat etiprate in Canada , with a focus on the treatment of carcinoid syndrome. This agreement represents an expansion of the licensing agreement previously entered into by Ipsen and Lexicon in October 2014 . Under the expanded alliance, Lexicon retains sole rights to commercialize telotristat etiprate in the United States and Japan .
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) decreased -3.51%, and closed at $1.10. The company holds the market capitalization of $797.66M. For the last twelve months, the stock was able to keep return on equity at -64.70%, while return on assets at -35.60%, in response to its return on investment at -25.60%. Its 20-day moving average gained 4.46%, below 50-day moving average of 12.77%, below 200-day moving average of -13.31% from the latest market price of $1.10. The mean recommendation of analysts for this stock is 2.10. (Where 1=Buy, 5=Sale).
Lexicon Pharmaceuticals, Inc. (LXRX) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
On March 16, 2015 Wayfair Inc (NYSE:W) one of the world’s largest online destinations for home furnishings and décor, proclaimed the winners of its Trade Tastemaker Awards. Wayfair partnered with leading interior designers Candice Olson, Jeffrey Alan Marks, and Windsor Smith to highlight the top up and coming talent in home design this year. The judges reviewed more than 4,500 submissions to determine the most notable designer in each of the following categories: Designer of the Year, Rising Star, Best Design Innovator, Best Use of Color, Best Design Solution, and Best Commercial Space.
Wayfair Inc (NYSE:W)’s shares picked down -63.42%, and closed at $31.94. The stock volatility for the week is 6.20%, while for the month remained 6.51%. The company holds consensus target price of $36.60.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -2.17 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -506.10%.
The mean recommendation of analysts for this stock is 2.00. (Where 1=Buy, 5=Sale).
Wayfair Inc (W) holds in the e-commerce business in the United States. It offers approximately seven million home products under various brands. The company’s brands include Wayfair.com that focuses on offering home furnishings and décor from low-to high-end and across various styles; Joss & Main, an online flash sales site; AllModern, an online destination for original design for modern home enthusiasts; DwellStudio, an online design studio for modern, fashion-forward home furnishings; and Birch Lane, a destination for classic style home designs. Wayfair Inc. also sells its products through retail partners.
On March 18, 2015 Cyberark Software Ltd (NASDAQ:CYBR) the company that protects organizations from cyber attacks that have made their way inside the network perimeter, disclosed that it was named a leader in the IDC MarketScape: Worldwide Privileged Access Management 2014 Vendor Assessment (doc #253303, December 2014). To download a free excerpt, please visit http://www.cyberark.com/privileged-access-management-market-leader/. The IDC MarketScape assesses vendors offering products in the privileged access management (PAM) market and notes that, “CyberArk is the PAM pure-play “big gorilla” with the most revenue and largest customer base.”
Cyberark Software Ltd (NASDAQ:CYBR) declined -3.41%, and closed at $48.69. The company has the market capitalization of $1.49 billion. On the other hand the stock’s volatility for the week is 5.56%, and for the month is 7.09%. The stock’s price to book ratio is $9.57, however price to sale ratio is $14.43. Analyst’s mean recommendation regarding this stock is 2.80. (Where 1=Buy, 5=Sale).
Cyberark Software Ltd (CYBR) develops, markets, and sells software-based IT security solutions that protect organizations from cyber attacks in the United States and internationally. The company offers privileged account security solution to secure, manage, and monitor privileged account access and activities.
Formerly on March 13, 2015 Ebix Inc (NASDAQ:EBIX) a leading international supplier of On-Demand software and E-commerce services to the insurance, financial and healthcare industries, uncovered results for the fiscal fourth quarter and fiscal year ended December 31, 2014.
Revenue: Total Q4 2014 revenue was $60.6 million, an increase of 19% on a year-over-year basis, as compared to Q4 2013 revenue of $50.8 million and an increase of $9.8 million over Q3 2014 revenues of $50.8 million.
Ebix Inc (NASDAQ:EBIX) fell -3.39%, and closed at $30.19. The stock has the beta value of 1.75, and its volatility for the week is 4.75%, while for the month it is 3.70%. The company has the market capitalization of $1.06 billion. The company holds the book value per share of 11.86, whereas cash per share is 1.49. Price to book ratio remained 2.55, while price to sale ratio is 4.97. Analysts mean recommendation for the stock is said to be 2.00 (where 1=Buy, 5=sale).
Ebix Inc (EBIX) offers software and e-commerce solutions to the insurance industry. The company operates data exchanges, which connect various entities within the insurance markets and enables the participant to carry and process data from one end to another in the areas of life insurance, annuities, employee health benefits, risk management, workers compensation, and property and casualty (P&C) insurance.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
